Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro

Show full item record



Permalink

http://hdl.handle.net/10138/330907

Citation

Schloer , S , Brunotte , L , Mecate-Zambrano , A , Zheng , S , Tang , J , Ludwig , S & Rescher , U 2021 , ' Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro ' , British Journal of Pharmacology , vol. 178 , no. 11 , pp. 2339-2350 . https://doi.org/10.1111/bph.15418

Title: Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro
Author: Schloer, Sebastian; Brunotte, Linda; Mecate-Zambrano, Angeles; Zheng, Shuyu; Tang, Jing; Ludwig, Stephan; Rescher, Ursula
Contributor organization: Research Program in Systems Oncology
Research Programs Unit
Faculty of Medicine
University of Helsinki
Date: 2021-06
Language: eng
Number of pages: 12
Belongs to series: British Journal of Pharmacology
ISSN: 0007-1188
DOI: https://doi.org/10.1111/bph.15418
URI: http://hdl.handle.net/10138/330907
Abstract: Background and Purpose The SARS-COV-2 pandemic and the global spread of coronavirus disease 2019 (COVID-19) urgently call for efficient and safe antiviral treatment strategies. A straightforward approach to speed up drug development at lower costs is drug repurposing. Here, we investigated the therapeutic potential of targeting the interface of SARS CoV-2 with the host via repurposing of clinically licensed drugs and evaluated their use in combinatory treatments with virus- and host-directed drugs in vitro. Experimental Approach We tested the antiviral potential of the antifungal itraconazole and the antidepressant fluoxetine on the production of infectious SARS-CoV-2 particles in the polarized Calu-3 cell culture model and evaluated the added benefit of a combinatory use of these host-directed drugs with the direct acting antiviral remdesivir, an inhibitor of viral RNA polymerase. Key Results Drug treatments were well-tolerated and potently impaired viral replication. Importantly, both itraconazole?remdesivir and fluoxetine?remdesivir combinations inhibited the production of infectious SARS-CoV-2 particles?>?90% and displayed synergistic effects, as determined in commonly used reference models for drug interaction. Conclusion and Implications Itraconazole?remdesivir and fluoxetine?remdesivir combinations are promising starting points for therapeutic options to control SARS-CoV-2 infection and severe progression of COVID-19.
Subject: 317 Pharmacy
combination therapy
drug repurposing
fluoxetine
itraconazole
remdesivir
SARS-CoV-2
VIRUS
CoV&#8208
2
CONCISE GUIDE
PHARMACOKINETICS
PHARMACOLOGY
INHIBITORS
SARS&#8208
Peer reviewed: Yes
Rights: cc_by_nc_nd
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
bph.15418.pdf 8.421Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record